Lightning Talk

Transforming how beef is produced is the single most effective action to address food’s contribution to climate change. Orbillion solves three fundamental challenges of the cell-cultured meat industry: production costs, scale-up, and sustainability. Our full stack technology platform is species agnostic and includes animal-free media, extended cell life, and high-density cell culture to unlock productivity and achieve price parity. Furthermore, we developed key technologies to create desirable product properties such as texture and flavor in our meat by combining synthetic biology and food science. Our deep understanding of the biology of animal cells enables us to create the taste and nutrition that consumers desire in meat products. First in the cultured meat industry, we established a strategic partnership to ensure sustainable production and are partnering with traditional meat producers to access the market of meat eaters.

"Our current food system is failing. The world’s healthiest foods are expensive, difficult to grow, and unattainable for many consumers. But the technologies many food companies have invested in to create and discover new food options have been primarily gimmicks, falling short on the needs for healthier options and creating novelty solutions instead of transformative ones. Companies can leverage technologies like synthetic biology, precision fermentation, and cellular cultivation in more productive ways that meet consumers where they are. Imagine a world where our most popular foods are also our healthiest, and where you could get the nutritional benefits of chocolate without the sugar. In this talk, Ayana Bio CEO Frank Jaksch will discuss how plant cell cultivation can make this a reality, and why food tech companies need to focus on high-impact ingredient solutions. "

Ailurus, the biocomputer company, now applies its technology to streamline protein engineering and production with unparalleled efficiency. Powered by designer cellular programs, the platform can assay a variety of protein properties at unprecedented scales in real life. To generate protein candidates, we integrated cutting-edge AI technologies for rational design, and also a collection of 20,000 domains for random screening. Following R&D, you can manufacture the products on our platform at flexible capacities, using FEGO™ for rapid scaling, and PandaPure®️ for purification at any scale. With Ailurus vec®️, a library of trillion vectors, you could further characterize expression landscape and optimize production cost in our proprietary bacterial hosts. From biopharmaceuticals to food substitutes, this cloud-lab service would enable developers to bring a biological product from concepts to the market without building local facilities. Join Ailurus to develop your protein products, and experience the future of bioprogramming today.

Form Bio's Chief Strategy Officer Claire Aldridge, PhD dives into the future of cell and gene therapy manufacturing, one enabled with AI models built to optimize therapy candidates for manufacturing so they can scale to meet real-world clinical conditions. While cell and gene therapies promise to revolutionize the worlds of rare disease, oncology and CNS disorders, these therapeutics are expensive, time-consuming and extremely iterative to manufacture and scale. AI technology is poised to provide for a more streamlined manufacturing process with the potential to drastically reduce time to market and R&D overspend.